Merrimack Pharma: Annual Report 2014 (Merrimack) - Mar 8, 2015 - “In February 2015, we stopped enrolling patients in this clinical trial prior to full enrollment based on a recommendation from the DSMB for the clinical trial, which cited shorter PFS on the treatment arm relative to the control arm in the overall patient population. We do not expect to enroll any new patients in this clinical trial. A preliminary analysis shows that a vast majority of the patients in this clinical trial were below the threshold of heregulin levels that we believe are necessary to benefit from MM-111”
Trial termination • Esophageal Cancer • Gastric Cancer • Oncology
|